Disease · MONDO_0007186

gastroesophageal reflux disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. gastroesophageal reflux disease. Diseases, record MONDO_0007186. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007186

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: gastroesophageal reflux disease; Open Targets
Open Targets ID: MONDO_0007186; Open Targets
Other names: Esophageal Reflux, GASTROESOPHAGEAL REFLUX DIS, GERD, Gastro Esophageal Reflux, Gastro oesophageal Reflux, Reflux, Gastro-Esophageal, Reflux, Gastro-oesophageal, Reflux, Gastroesophageal, acid reflux, gastroesophageal reflux, reflux; Open Targets
Disease Ontology: DOID:8534; Disease Ontology
MeSH: D005764; MeSH
NCI Thesaurus: C26781; NCI Thesaurus
Highest stage of its drugs: Approval, for 46 of its 96 drugs, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Drugs96

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ESOMEPRAZOLE	CHEMBL1201320	Small molecule	Approval	ATC and EMA Human Drugs	62	60	58	Drugs and targets
PANTOPRAZOLE	CHEMBL1502	Small molecule	Approval	ATC, EMA Human Drugs and TTD	38	31	31	Drugs and targets
OMEPRAZOLE	CHEMBL1503	Small molecule	Approval	ATC, DailyMed and TTD	122	24	24	Drugs and targets
LANSOPRAZOLE	CHEMBL480	Small molecule	Approval	ATC and DailyMed	40	23	23	Drugs and targets
RABEPRAZOLE	CHEMBL1219	Small molecule	Approval	ATC	21	19	19	Drugs and targets
DEXLANSOPRAZOLE	CHEMBL1201863	Small molecule	Approval	ATC and DailyMed	23	18	18	Drugs and targets
VONOPRAZAN	CHEMBL2079130	Small molecule	Approval	ATC	19	17	17	Drugs and targets
RABEPRAZOLE SODIUM	CHEMBL1200930	Small molecule	Approval	DailyMed	29	10	10	Drugs and targets
TEGOPRAZAN	CHEMBL4297583	Small molecule	Approval	ATC	8	7	7	Drugs and targets
VONOPRAZAN FUMARATE	CHEMBL2064032	Small molecule	Approval	PMDA	6	5	5	Drugs and targets

1 to 10 of 96

See all 96 drugs

Targets53

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ATP4A	Potassium-transporting ATPase	16	Potassium-transporting ATPase blocker; Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	16	Potassium-transporting ATPase blocker; Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/496	Drugs and targets
HRH2	Histamine H2 receptor	6	Histamine H2 receptor antagonist	Approval	https://conductscience.org/library/genes/3274	Drugs and targets
HTR4	5-hydroxytryptamine receptor 4	6	Serotonin 4 (5-HT4) receptor agonist; Serotonin 4 (5-HT4) receptor partial agonist	Approval	https://conductscience.org/library/genes/3360	Drugs and targets
SLC6A4	Sodium-dependent serotonin transporter	5	Serotonin transporter inhibitor	Phase 2/3	https://conductscience.org/library/genes/6532	Drugs and targets
SLC6A2	Sodium-dependent noradrenaline transporter	4	Norepinephrine transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6530	Drugs and targets
GABBR1	GABA-B receptor	3	GABA-B receptor 1 agonist; GABA-B receptor agonist	Phase 3	https://conductscience.org/library/genes/2550	Drugs and targets
GABBR2	GABA-B receptor	3	GABA-B receptor 2 agonist; GABA-B receptor agonist	Phase 3	https://conductscience.org/library/genes/9568	Drugs and targets
GRM5	Metabotropic glutamate receptor 5	3	Metabotropic glutamate receptor 5 antagonist; Metabotropic glutamate receptor 5 modulator	Phase 2	https://conductscience.org/library/genes/2915	Drugs and targets
HTR3A	5-hydroxytryptamine receptor 3A	3	Serotonin 3 (5-HT3) receptor antagonist; Serotonin 3 (5-HT3) receptor partial agonist; Serotonin 3a (5-HT3a) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3359	Drugs and targets

1 to 10 of 53

See all 53 targets

Trials250

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01990339	Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia Symptoms		14,965	2014-11-11	Gastroesophageal Reflux Disease With Dyspepsia Symptoms	LANSOPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00829738	Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease		4,188	2010-09-24	Gastroesophageal Reflux Disease	PANTOPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03214952	Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"		3,183	2019-12-12	Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis	VONOPRAZAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00444275	Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients	Phase 4	3,029	2012-12-11	GERD	ESOMEPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01669811	Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)	Phase 3	1,398	2015-08-14	Refractory Reflux Esophagitis	ESOMEPRAZOLE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03214081	Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"		1,237	2019-10-23	Reflux Esophagitis	VONOPRAZAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT04124926	Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis	Phase 3	1,027	2022-07-29	Erosive Esophagitis	LANSOPRAZOLE, VONOPRAZAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00317044	Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma	Phase 2	961	2014-06-09	Asthma, GERD	ESOMEPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00251745	Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn	Phase 3	908	2009-03-23	Gastroesophageal Reflux Disease	DEXLANSOPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00251758	Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn	Phase 3	908	2009-03-23	Gastroesophageal Reflux Disease	DEXLANSOPRAZOLE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 250

See all 250 trials

Comparisons in its trials89

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Placebo BID + PPIs vs 1500 mg IW-3718 BID + PPIs: deaths from any cause	1 of 304	0 of 304	608	NCT03561883	Trial comparisons
Placebo BID + PPIs vs 1500 mg IW-3718 BID + PPIs: serious adverse events	3 of 304	2 of 304	608	NCT03561883	Trial comparisons
Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Los Angeles (LA) Grade 'B' at 5 Year Visit	5 of 288	7 of 266	554	NCT00251927	Trial comparisons
Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Investigator-assessed Heartburn Severity at 5 Year Visit, Participants With no Heartburn	163 of 288	161 of 266	554	NCT00251927	Trial comparisons
Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Los Angeles (LA) Grade 'Normal' at 5 Year Visit	144 of 288	158 of 266	554	NCT00251927	Trial comparisons
Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Investigator-assessed Heartburn Severity at 5 Year Visit, Participants With Severe Heartburn	0 of 288	2 of 266	554	NCT00251927	Trial comparisons
Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Investigator-assessed Heartburn Severity at 5 Year Visit, Participants With Moderate Heartburn	3 of 288	3 of 266	554	NCT00251927	Trial comparisons
Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Number of Participants With Treatment Failure at 5 Years	33 of 288	19 of 266	554	NCT00251927	Trial comparisons
Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Los Angeles (LA) Grade 'A' at 5 Year Visit	12 of 288	16 of 266	554	NCT00251927	Trial comparisons
Esomeprazole Surgical Arm vs Esomeprazole Medical Arm: Investigator-assessed Heartburn Severity at 5 Year Visit, Participants With Mild Heartburn	11 of 288	25 of 266	554	NCT00251927	Trial comparisons

1 to 10 of 89

See all 89 comparisons in its trials

Papers from its trials142

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36117573	RESULT	1	PubMed
36057730	RESULT	1	PubMed
35979162	RESULT	1	PubMed
35184616	RESULT	1	PubMed
34642267	RESULT	1	PubMed
33705573	RESULT	1	PubMed
33029166	RESULT	1	PubMed
32095968	RESULT	1	PubMed
30504527	RESULT	1	PubMed
30094626	RESULT	1	PubMed

1 to 10 of 142

See all 142 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007186

GET https://conductscience.org/api/diseases/v1/MONDO_0007186/drugs?page=2

API reference For AI assistants